UNICA IRIS Institutional Research Information System

FRAU, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 77.728
NA - Nord America 2.528
AS - Asia 389
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 4
SA - Sud America 4
OC - Oceania 2
Totale 80.661
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 77.071
US - Stati Uniti d'America 2.513
CN - Cina 268
UA - Ucraina 254
SE - Svezia 183
SG - Singapore 66
FI - Finlandia 61
DE - Germania 58
GB - Regno Unito 55
IN - India 17
VN - Vietnam 16
CA - Canada 14
FR - Francia 12
BE - Belgio 8
CZ - Repubblica Ceca 7
KR - Corea 7
RU - Federazione Russa 7
EU - Europa 6
HK - Hong Kong 5
EG - Egitto 4
IR - Iran 4
BD - Bangladesh 3
NL - Olanda 3
PL - Polonia 3
RO - Romania 3
JP - Giappone 2
AU - Australia 1
BO - Bolivia 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
EC - Ecuador 1
IE - Irlanda 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MX - Messico 1
NZ - Nuova Zelanda 1
Totale 80.661
Salva come PNG Salva come JPEG
Città #
Cagliari 75.875
Uta 1.054
Woodbridge 294
Fairfield 287
Chandler 264
Ann Arbor 143
Ashburn 142
Jacksonville 137
Nyköping 136
Houston 130
Seattle 123
Boardman 117
Wilmington 117
Dearborn 101
Cambridge 97
New York 62
Singapore 46
Nanjing 40
Santa Clara 40
Shanghai 34
Beijing 30
Boston 29
Helsinki 24
Guangzhou 20
Los Angeles 20
Shenyang 20
Redwood City 19
Milan 18
San Diego 18
Dong Ket 16
Hebei 13
Jinan 13
Norwalk 12
Jiaxing 11
Mountain View 10
Toronto 10
Changsha 9
Nanchang 9
Brussels 8
Orange 8
Verona 7
London 6
Ningbo 6
Oristano 6
Padova 6
Tianjin 6
Wuhan 6
Hangzhou 5
Modrice 5
Pune 5
Zhengzhou 5
Chengdu 4
Gurgaon 4
Hong Kong 4
Kunming 4
Rome 4
Sassari 4
Seoul 4
Auburn Hills 3
Baveno 3
Cracow 3
Dhaka 3
Hefei 3
Jinhua 3
Millbury 3
Monopoli 3
Phoenix 3
Saint Petersburg 3
San Jose 3
San Mateo 3
Sestu 3
Washington 3
Assèmini 2
Atlanta 2
Augusta 2
Brixen 2
Camerino 2
Cedar Knolls 2
Chicago 2
Clifton 2
Council Bluffs 2
Escolca 2
Falls Church 2
Fuzhou 2
Gonnosfanadiga 2
Indiana 2
Indianapolis 2
Munich 2
Palo Alto 2
Prescot 2
Redmond 2
Salerno 2
Shaoxing 2
Stockholm 2
Suceava 2
Tappahannock 2
Aci Catena 1
Acton 1
Almaty 1
Amsterdam 1
Totale 79.741
Salva come PNG Salva come JPEG
Nome #
Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence 3.365
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.157
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.074
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 2.991
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 2.901
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.798
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.738
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.612
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.590
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.589
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.554
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.522
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.520
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.428
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.398
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.337
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.139
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.096
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.039
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.012
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.006
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.004
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.868
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.865
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.784
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.783
Effect of adenosine A1 and A2A antagonists on 3,4 methylenedioxymethamphetamine (MDMA)-induced neuroinflammation and dopamine neuron toxicity in mouse brain 1.683
null 1.651
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.608
Caffeine potentiation of 3,4-methylenedioxymethamphetamine (MDMA) toxicity: role of age 1.563
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.554
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.303
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.198
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.184
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.110
Caffeine potentiates 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-induced-glial activation: role of age and adenosine A1 and A2A receptors 1.060
null 981
Role of Adenosine A1 and A2A receptors on 3,4-methylendioxymeth-amphetamine (MDMA, Ecstasy)-induced neurotoxicity, astroglia and microglia reactivity in mouse striatum and substantia nigra 952
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 803
Behavioural and biochemical correlates of high and low dyskinetic parkinsonian drugs 525
Behavioural correlates of dopaminergic agonists dyskinetic potential in the 6-OHDA lesioned rat 265
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 207
Totale 80.817
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.409
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.245 0 0 0 0 0 4.126 2.241 438 280 392 267 501
2020/202118.608 610 703 897 6.131 3.938 1.682 1.394 875 356 692 741 589
2021/20223.751 333 284 320 195 175 273 388 277 220 327 355 604
2022/20236.193 733 1.043 648 465 559 542 292 340 399 419 526 227
2023/20245.262 280 370 195 305 541 849 831 336 236 374 392 553
2024/20255.734 1.324 1.426 1.166 910 527 381 0 0 0 0 0 0
Totale 80.817